The Tomazou lab, at the St. Anna Children's Cancer Research Institute in the medical hub of Vienna, aims to establish an epigenome-based precision medicine program for pediatric sarcomas.
The goal of our research group is to uncover the roles of epigenetic deregulation as an oncogenic mechanism, with a focus on fusion-driven pediatric sarcomas. We study how fusion proteins rewire healthy cells for malignancy, with the perspective of exploiting this knowledge for improving pediatric sarcoma therapy. We are applying state-of-the-art technologies that combine wet-lab and computational methods investigating:
-
Non-genetic mechanisms of tumor formation orchestrated by oncogenic fusion proteins
-
Contribution of the cellular state of the corresponding cell of origin to cancer development
-
Epigenetic heterogeneity as source of cellular plasticity providing novel therapeutic paradigms
-
Non-genetic based biomarkers for patient stratification and real time disease monitoring
For more details on published work, please also see our publications.
Single-cell technologies

Disease modelling of fusion-driven sarcomas & cell-of-origin
